Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Even among those with more comorbidities, safety, efficacy of treatment remained.
Researchers compared the efficacy and nephrotoxicity of R-DHAP vs R-DHAOx among patients treated for NHL between 2007 and 2014.
SEER analysis reveals age, Ann Arbor stage, and chemotherapy as critical factors affecting prognosis in patients with primary cardiac lymphoma.
Nivolumab-based first-line treatment may result in high remission and progression-free survival rates in early-stage unfavorable classic Hodgkin lymphoma.
Hypercalcemia is not uncommon in patients with de novo diffuse large B-cell lymphoma and may be linked to a higher risk for other adverse events.
Combined targeted agents with immune regulators and chimeric antigen receptor cell–based therapies may improve overall survival for patients with PTCL.
Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.
Researchers oulined changes in diagnostics, surveillance, and treatment practices that could lead to better outcomes for patients with NHL in sub-Saharan Africa.
Researchers found that dose-adjusted (DA-) etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) for B-cell lymphomas can be administered safely in the outpatient setting and that outpatient administration was associated with significant savings relative to inpatient administration. Wenhui Li, PharmD, of the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues published their findings in…
There is clinical and real-world evidence that indicates some patients do not complete treatment for reasons other than lack of response.
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
Researchers conducted a 2-year safety and efficacy follow-up analysis to determine whether long-term data support the initial toxicity findings.
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.
Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Overall survival at 5 years was 100% with the reduced-intensity conditioning regimen compared with 48.5% with the myeloablative conditioning regimen.
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Progression-free survival was superior with lenalidomide compared with placebo, while health-related quality of life was similar and did not change during the study.
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Researchers characterized outcomes for enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, and peripheral gamma delta T-cell lymphoma.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
The combination warrants no further study in these patients.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.